SEC Comment Letter 0000000000-23-012755 to Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc.
Date: Nov. 21, 2023 · CIK: 0001799448 · Accession: 0000000000-23-012755
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275636
Letter
United States securities and exchange commission logo November 21, 2023 Lawrence M. Blatt, Ph.D. Chairman and Chief Executive Officer Aligos Therapeutics, Inc. One Corporate Dr., 2nd Floor South San Francisco, CA 94080 Re:Aligos Therapeutics, Inc. Registration Statement on Form S-3 Filed November 17, 2023 File No. 333-275636 Dear Lawrence M. Blatt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Mark V. Roeder, Esq.
Show Raw Text
United States securities and exchange commission logo
November 21, 2023
Lawrence M. Blatt, Ph.D.
Chairman and Chief Executive Officer
Aligos Therapeutics, Inc.
One Corporate Dr., 2nd Floor
South San Francisco, CA 94080
Re:Aligos Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 17, 2023
File No. 333-275636
Dear Lawrence M. Blatt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mark V. Roeder, Esq.